Results 31 to 40 of about 65,459 (255)

Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus [PDF]

, 2015
Introduction ES-62, a phosphorylcholine (PC)-containing immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, protects against nephritis in the MRL/Lpr mouse model of systemic lupus erythematosus (SLE).
Harnett, M. M., Harnett, W., Pineda, M. A., Rodgers, D. T., Suckling, C. J.   +4 more
core   +1 more source

Identifying chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knockout mice [PDF]

, 2004
Chemokines, in concert with cytokines and adhesion molecules, play multiple roles in local and systemic immune responses. In the kidney, the temporal and spatial expression of chemokines correlates with local renal damage and accumulation of chemokine ...
Abdi R, Anders HJ, Anders HJ, Anders HJ, Bruhl H, Burne-Taney MJ, Feng L, Fituri O, Fujinaka H, Garcia GE, Grone HJ, Keane MP, Mack M, Miura M, Murphy PM, Nath KA, Perez de Lema G, Rollins BJ, Romagnani P, Segerer S, Segerer S, Segerer S, Tang WW, Taub DD, Tesch GH, Tokuda A, Topham PS, Vielhauer V, Vielhauer V, Wada T, Wang Y, Wenzel U, Wu X, Wu X, Zernecke A   +34 more
core   +1 more source

Lupus nephritis: current issues [PDF]

Annals of the Rheumatic Diseases, 2003
Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside ...
Mavragani, C.P., Moutsopoulos, H.M.
openaire   +3 more sources

Lupus Nephritis in Children: Novel Perspectives

Medicina, 2023
Childhood-onset systemic lupus erythematosus is an inflammatory and autoimmune condition characterized by heterogeneous multisystem involvement and a chronic course with unpredictable flares.
Marco Pennesi, Simone Benvenuto
doaj   +1 more source

B cells in SLE. Different biological drugs for different pathogenic mechanisms [PDF]

, 2007
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major players. Recently,
Carsetti, Rita, Picchianti Diamanti, Andrea, Rosado, M. Manuela, Valesini, Guido   +3 more
core   +1 more source

Spectrum of renal vascular lesions among patients with lupus nephritis: An experience from a tertiary care center

Indian Journal of Pathology and Microbiology, 2023
Background: Lupus nephritis (LN) is the assemblage of glomerular, tubulointerstitial and vascular changes. Despite the fact that glomerular changes are overemphasized in pathological classification and scoring system, but the existence of vascular damage
Madhumita Paul, Soma Addya, Moumita Sengupta, Keya Basu, Arpita Roychowdhury, Manimoy Bandopadhyay   +5 more
doaj   +1 more source

Lupus nephritis

Kidney International, 1997
Contains fulltext : 24337___.PDF (Publisher’s version ) (Open Access)
openaire   +3 more sources

Neutrophil gelatinase-associated lipocalin is a urine-based biomarker for diagnosing active lupus nephritis

Bangabandhu Sheikh Mujib Medical University Journal
Background: Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE). Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a non-invasive biomarker that may aid in diagnosing active lupus nephritis.
Anthony Chakma, Debatosh Paul, Sheuly Ferdoushi, Minhaj Rahim Choudhury, Md. Saiful Islam   +4 more
doaj   +1 more source

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus [PDF]

, 2018
Background: Systematic lupus erythematosus (SLE) is characterized with various complications which can cause serious organ damage in the human body. Despite the significant improvements in disease management of SLE patients, the non-invasive diagnosis ...
Burkly, L.C., Mischak, H., Mullen, W., Pejchinovski, M., Petri, M.A., Siwy, J., Wei, R.   +6 more
core   +1 more source

Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study. [PDF]

, 2020
BACKGROUND:Systemic lupus erythematous (SLE) disproportionately impacts patients of color and socioeconomically disadvantaged patients. Similar disparities in HIV were reduced through a World Health Organization-endorsed Care Continuum strategy targeting
Ahmad, Umber, Bartels, Christie M, Chang, Ian, Ezeh, Nnenna, Garg, Shivani, Kind, Amy, Rosenthal, Ann, Schletzbaum, Maria, Wang, Xing   +8 more
core